Program
+ EXPAND all sections 
To expand/collapse individual sections, click the section title or grey arrow.
Sunday, 11 October
Visit the registration desk to check in on Sunday, which allows you to jump-start your networking opportunities at the Welcome Drinks Reception in the Benjamin Britten Lounge on the 3rd Floor.
By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Monday morning.
The 17th Annual BioPartnering Europe will be opened by a reception in the Benjamin Britten Lounge, on the 3rd Floor.
Monday, 12 October
Join us for a refreshing continental breakfast of fresh fruit juices, and breakfast pastries accompanied by sweet cream butter. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.
The conference will open with a welcome address and highlights on "The UK Advantage - why the UK is the best location in Europe for bio-business".
Speaker:
Dr. Robert Lee Kilpatrick, Partner, Technology Vision Group LLC
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
Title: Planning for Economic Resurgence
A great deal of energy has been spent over the last year discussing and planning for the meltdown that has been taking place in the financial markets, thereby impeding private companies from going public, and existing public companies from raising cash.
These expected infusions of equity were destined to support existing and planned pipeline advancements as well as acquisitions. However, there is a great deal of institutional and venture money sitting on the sidelines awaiting some complex set of constantly changing and unknowable signals before freeing up the cash. In the meantime, mid-size and larger pharmas have been buying companies and licensing products and technologies at a torrid pace… perhaps taking advantage of the actions of financial players?
The Panel, comprised of industry experts from biotech and pharma alike, has been convened to discuss its views on how to plan for the expected resurgence of the capital markets and corporate transactional activity.
Chair:
Mr. William J. Kridel, Managing Director, Ferghana Partners Group
Buses depart the QEII Conference Centre for the Reception.
| From Ben Franklin to Brad Pitt, BPE delegates can rub shoulders with the rich and famous at this popular museum, which casts lifelike wax figures in realistic settings. Delegates will be able to enjoy a night out with the stars while enjoying drinks and heavy hors d'oeuvres. |
 |
Buses will return delegates to the City Inn Westminster Hotel.
No transportation will be provided to any other location in the London area. Delegates will be responsible for transportation to other accommodations. |
 |
Tuesday, 13 October
Join us for a refreshing continental breakfast of fresh fruit juices, and breakfast pastries accompanied by sweet cream butter. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.
Title: Building on a Firm Foundation
Takeda Pharmaceuticals was founded 228 years ago and became a pharmaceutical manufacturer in 1895. Whilst it is well-known that Takeda is Japan’s number 1 pharmaceutical company, it also has a long history of expansion outside Japan. Takeda entered the European market in 1978 when it established a joint venture in France, followed by Germany and Italy. In 1997, a manufacturing operation was opened in Ireland. In 2006, as part of Takeda’s global expansion policy, Takeda Pharmaceuticals Europe Ltd (TPEU) was established in London to drive the growth of the existing affiliates (Germany, France, Italy, UK, Switzerland and Austria) and to expand its European footprint. In April 2009, TPEU announced the establishment of Takeda Spain. Other countries are slated to follow. Mr. Agosti will describe Takeda’s current capabilities in Europe and how he envisages the future for Takeda as a global pharmaceutical company with origins in Japan.
Speaker:
Mr. Marcello Agosti, Corporate Strategy Director, Takeda Pharmaceuticals Europe
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Ms. Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co., Inc.
Title: Pfizer Company Presentation
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Mr. Chris D. Brown, Director, Worldwide Business Development, Pfizer Inc.
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Dr. Corinne Savill, Head of Global Search & Evaluation BD&L, Novartis Pharma AG
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
In these dedicated presentations, biotechnology companies from around the world have the opportunity
to briefly introduce their company, highlight key technologies,
alliances, and where they stand with product & clinical
developments.
Title: Licensing “White Space” Opportunities—What does it take?
Roche and Plexxikon announced a second partnership deal at the beginning on 2009 to commercialize a novel kinase inhibitor, PLX5568, for polycystic kidney disease (PKD), currently in Phase 1 human clinical trials. This asset is being developed for a disease with a high unmet need; there is currently no treatment for PKD. On reviewing compelling data for PLX5568, Roche made the strategic decision to open up metabolic disease to include renal disease, demonstrating its commitment to in-licensing promising new clinically differentiated compounds in areas of high unmet need. For Plexxikon, this second deal with Roche builds on the success of the first, and was a great deal financially in the current environment ($60mm upfront payment with $275mm in potential milestones relating to PKD).
Kathy Glaub and Andrew Sleight will describe the evolution of the relationship and provide insights into building on an already successful alliance.
Speaker: Mrs. Kathleen Sereda Glaub, President, Plexxikon
Speaker: Mr. Andrew Sleight, Disease Biology Area Leader Metabolic Diseases, F. Hoffmann - La Roche Ltd.
Title: GSK- challenges and opportunities in the Emerging Markets
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
In this presentation, the speaker will highlight the strengths of their company, which may include a company overview, an outline of products on the market, and information about alliances, existing or sought.
Speaker:
Mr. John O'Connor, Executive Director, External R&D Affairs Group, Amgen
Title: Autumn Market Report
A complete review of the Life and Health Sciences sector across Europe, including comparisons with the US. Metrics will be presented and leading members of the professional investment community will provide commentary and predictions for the coming six months. This event, and the drinks reception which follows, is being offered to invited guests at no charge.
Chair: Mr. Stuart Henderson, Partner, Deloitte Life Sciences and Health Care
Speaker: Dr. Sam Fazeli, Head of European Equity Research, Piper Jaffray Ltd.
Speaker: Mr. John Hodgson, Director, Critical I Limited
Speaker: Mr. Antoine Papiernik, Managing Partner, Sofinnova Partners
Speaker: Dr. Andy Richards, , Private Investor
An opportunity to say goodbye to fellow delegates and begin planning for the 18th Annual BioPartnering Europe in Fall 2010.
